Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arthritis interception with Guselkumab in subclinical psoriatic arthritis
2025-523551-54-00Phase 4Authorised
- Sponsor
- Azienda sanitaria universitaria Friuli Centrale
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of guselkumab in plaque psoriasis and psoriatic arthritis (PsA), sponsored by Azienda sanitaria universitaria Friuli Centrale. Primary endpoint: Resolution of arthralgia and change in UPsA activity score at Week 24. Planned start Jan 2026; status: authorised.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-523551-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523551-54-00.